骨质疏松症的新型疗法——合成代谢药物( 七 ) 本文重点?骨吸收抑制药物如双膦酸盐

[22]Nioi, P. et al. Transcriptional profiling of laser capture microdissected subpopulations of the osteoblast lineage provides insight into the early response to sclerostin antibody in rats. J. Bone Miner. Res. 30,1457–1467 (2015).
[23]Chavassieux, P. et al. Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J. Bone Miner. Res. 34,1597–1608 (2019).
[24]Wang, B., Yang, Y., Abou-Samra, A. B.--tt-darkmode-color: #7B7F83;">[25]Bonafede, M. M. et al. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis. Osteoporos. Int. 26, 1203–1212(2015).
[26]Cosman, F. et al. Hip and spine strength effects of adding versus switching to teriparatide in
postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J. Bone Miner.Res. 28, 1328–1336 (2013)
[27]Cosman, F. et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26,503–511 (2011).
【骨质疏松症的新型疗法——合成代谢药物】[28]Cosman, F., Nieves, J. W.--tt-darkmode-color: #7B7F83;">[29]Eastell, R. et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol.Metab. 104, 1595–1622 (2019)